Outcome of selected breast cancer patients with micrometastasis or isolated tumor cells in sentinel node biopsy and no completion axillary lymph node dissection

2010 ◽  
Vol 102 (3) ◽  
pp. 215-219 ◽  
Author(s):  
Tuomo J. Meretoja ◽  
Jaana H. Vironen ◽  
Päivi S. Heikkilä ◽  
Marjut H. Leidenius
2006 ◽  
Vol 13 (4) ◽  
pp. 475-479 ◽  
Author(s):  
Maartje C. van Rijk ◽  
Omgo E. Nieweg ◽  
Emiel J. T. Rutgers ◽  
Hester S. A. Oldenburg ◽  
Renato Valdés Olmos ◽  
...  

2017 ◽  
Vol 57 (1) ◽  
pp. 166-169 ◽  
Author(s):  
Christina Jessing ◽  
Linnea Langhans ◽  
Maj-Britt Jensen ◽  
Maj-Lis Talman ◽  
Tove Filtenborg Tvedskov ◽  
...  

2021 ◽  
Vol 10 ◽  
Author(s):  
Shi-Ping Luo ◽  
Jie Zhang ◽  
Qi-Sen Wu ◽  
Yu-Xiang Lin ◽  
Chuan-Gui Song

BackgroundSurvival in elderly patients undergoing sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) has not been specifically analyzed. This study aimed to explore the association between different types of axillary lymph node (ALN) evaluations and survival of elderly breast cancer patients.MethodsA retrospective cohort study was conducted of invasive ductal breast cancer patients 70 years and older in the Surveillance, Epidemiology, and End Results database (2004–2016). Analyses were performed to compare the characteristics and survival outcomes of patients who received surgical lymph node dissection and those who did not. Breast cancer specific survival (BCSS) and overall survival were compared by using Cox proportional hazards regression analysis and propensity score matching (PSM) methods to account for selection bias from covariate imbalance.ResultsOf the 75,950 patients analyzed, patients without ALN evaluation had a significantly worse prognosis, while there was no significant difference for BCSS between using a sentinel lymph node biopsy (SLNB) and an axillary lymph node dissection (ALND) after adjustment for known covariates [adjusted hazard ratio (HR) = 0.991, 95% confidence interval (CI) = 0.925–1.062, p = 0.800]. In the stratification analyses after PSM, the ALND did not show a significant BCSS advantage compared with SLNB in any subgroups except for the pN1 stage or above. Furthermore, after PSM of the pN1 stage patients, SLNB was associated with a significantly worse BCSS in hormone receptor negative (HR−) patients (HR = 1.536, 95%CI = 1.213–1.946, p < 0.001), but not in the hormone receptor positive (HR+) group (HR = 1.150, 95%CI = 0.986–1.340, p = 0.075).ConclusionIn our study, ALND does not yield superior survival compared with SLNB for elderly patients with pN1 stage HR+ breast cancer. Although our findings are limited by the bias associated with retrospective study design, we believe that in the absence of results from randomized clinical trials, our findings should be considered when recommending the omission of ALND for elderly breast cancer patients.


Breast Cancer ◽  
2019 ◽  
Vol 27 (2) ◽  
pp. 284-290 ◽  
Author(s):  
Yoshiteru Akezaki ◽  
Eiji Nakata ◽  
Masato Kikuuchi ◽  
Ritsuko Tominaga ◽  
Hideaki Kurokawa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document